Founded in 2011, Globavir has multiple licenses from Stanford University and acquired BioCycive in 2014, partnering with Sorrento Therapeutics in 2015 and Bio-Rad in 2016. Their focus is on the treatment of dengue virus infection, but they also research and develop therapeutics for other infectious diseases such as West Nile, chikungunya, and Ebola, as well as cancer. Globavir uses the 505(b)2 regulatory pathway for rapid development of new therapies and has identified candidate compounds for additional viral indications.